title: Does Vidarabine Mediate Cardioprotection via Inhibition of AC5?
abstract: There is an ongoing discussion about the value of adenylyl cyclase 5 (AC5) as drug target for treatment of heart failure. This letter discusses statistical, pharmacokinetic, and pharmacodynamic reasons why the recently proposed cardioprotective effects of vidarabine cannot be readily attributed to AC5 inhibition.
authors.affiliation: Institute of Pharmacology, Hannover Medical School, Hannover, Germany seifert.roland@mh-hannover.de.
authors.forename: Roland
authors.initials: R
authors.lastname: Seifert
mesh_terms: D000067956:Adenylyl Cyclase Inhibitors; D000262:Adenylyl Cyclases; D006333:Heart Failure; D006801:Humans; D014740:Vidarabine
chemical_list: D000067956:Adenylyl Cyclase Inhibitors; D000262:Adenylyl Cyclases; D014740:Vidarabine